Elimusertib

DB19041InvestigationalSmall molecule

Elimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase ATR
Curator reviewed
Formula / weight: C₂₀H₂₁N₇O · 375.436 g/mol (avg)
Also known as: 1,7-naphthyridine, 2-((3r)-3-methyl-4-morpholinyl)-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-3-yl)-
Code names: BAY-1895344

Resolves to

Compound

Structure

InChIKeyYBXRSCXGRPSTMW-CYBMUJFWSA-NSMILESC[C@@H]1COCCN1C1=NC2=C(N=CC=C2C(=C1)C1=CC=NN1C)C1=CC=NN1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elimusertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.